{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:31:32Z","timestamp":1780050692687,"version":"3.53.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12879-017-2438-1","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T06:45:48Z","timestamp":1494225948000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Promoting notification and linkage of HBs antigen and anti-HCV antibody-positive patients through hospital alert system"],"prefix":"10.1186","volume":"17","author":[{"given":"Naoki","family":"Yoshioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsura","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuro","family":"Kaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Hirosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kunii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setsuo","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hirooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"issue":"10049","key":"2438_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet. 2016;388(10049):1081\u20138.","journal-title":"Lancet"},{"issue":"12","key":"2438_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection. New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212\u20139.","journal-title":"Vaccine"},{"issue":"4","key":"2438_CR3","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection. New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342.","journal-title":"Hepatology"},{"issue":"1","key":"2438_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261\u201383.","journal-title":"Hepatology"},{"issue":"3","key":"2438_CR5","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"C Hepatitis","year":"2015","unstructured":"Hepatitis C. Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932\u201354.","journal-title":"Hepatology"},{"key":"2438_CR6","unstructured":"Combating hepatitis B and C to reach elimination by 2030. World Health Organization. \nhttp:\/\/apps.who.int\/iris\/bitstream\/10665\/206453\/1\/WHO_HIV_2016.04_eng.pdf\n\n. Accessed\u00a027 May 2016."},{"key":"2438_CR7","unstructured":"Tanaka J. the 13th Council on Promotion of Hepatitis Measures. \nhttp:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10905750-Kenkoukyoku-Kanentaisakusuishinshitsu\/0000075723.pdf\n\n. Accessed 26 Feb 2015."},{"issue":"5","key":"2438_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2957\/kanzo.54.307","volume":"54","author":"N Furukawa","year":"2013","unstructured":"Furukawa N, Kawaguchi Y, Oeda S, Izumi N, Eguchi H, Mizuta T, et al. Current management practices for HBs antigen or anti-HCV antibody positive individuals in non-hepatology departments at a university hospital. Kanzo. 2013;54(5):307\u201316.","journal-title":"Kanzo"},{"key":"2438_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2957\/kanzo.56.137","volume":"56","author":"Y Shimomura","year":"2015","unstructured":"Shimomura Y, Ikeda F, Nouso K, Takaki A, Watanabe T, Iwatsuki K, et al. Introduction of management system of positive test results for HBV and HCV infection in electronic medical chart. Kanzo. 2015;56:137\u201343.","journal-title":"Kanzo."},{"key":"2438_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12879-016-1765-y","volume":"16","author":"H Fujii","year":"2016","unstructured":"Fujii H, Yamaguchi S, Kurai O, Miyano M, Ueda W, Oba H, et al. Putting \"sticky notes\" on the electronic medical record to promote intra-hospital referral of hepatitis B and C virus-positive patients to hepatology specialists: an exploratory study. BMC Infect Dis. 2016;16:410.","journal-title":"BMC Infect Dis"},{"issue":"Suppl 2","key":"2438_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/00333549161310S202","volume":"131","author":"G Ramirez","year":"2016","unstructured":"Ramirez G, Cabral R, Patterson M, Schoenbachler BT, Bedell D, Smith BD, et al. Early identification and linkage to Care for People with chronic HBV and HCV infection: the HepTLC initiative. Public Health Rep. 2016;131(Suppl 2):5\u201311.","journal-title":"Public Health Rep"},{"issue":"1","key":"2438_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98\u2013107.","journal-title":"Hepatology"},{"issue":"11","key":"2438_CR13","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jvh.12312","volume":"21","author":"M Omata","year":"2014","unstructured":"Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762\u20138.","journal-title":"J Viral Hepat"},{"issue":"6","key":"2438_CR14","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2438_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jgh.13073","volume":"31","author":"H Kumada","year":"2016","unstructured":"Kumada H, Suzuki F, Suzuki Y, Toyota J, Karino Y, Chayama K, et al. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon\/ribavirin in Japanese hepatitis C virus patients. J Gastroenterol Hepatol. 2016;31(1):14\u201322.","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"2438_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1478-3231.2008.01941.x","volume":"29","author":"YF Liaw","year":"2009","unstructured":"Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29(Suppl 1):100\u20137.","journal-title":"Liver Int"},{"issue":"3","key":"2438_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/eurpub\/ckp001","volume":"19","author":"G Sroczynski","year":"2009","unstructured":"Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, Wright D, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Pub Health. 2009;19(3):245\u201353.","journal-title":"Eur J Pub Health"},{"issue":"3","key":"2438_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.23561","volume":"51","author":"AE Mitchell","year":"2010","unstructured":"Mitchell AE, Colvin HM, Palmer BR. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51(3):729\u201333.","journal-title":"Hepatology"},{"key":"2438_CR19","unstructured":"Basic Act on Hepatitis Measures. Ministry of Justice. 2009. \nhttp:\/\/www.japaneselawtranslation.go.jp\/law\/detail\/?id=1995\n\n. Accessed 4 Dec 2009."},{"issue":"12","key":"2438_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2957\/kanzo.57.634","volume":"57","author":"T Kaishima","year":"2016","unstructured":"Kaishima T, Fujii T, Matsuoka T, Sakamune K, Nagashima S, Yamamoto C, et al. Study of the issues of receiving hepatitis screening and the rate of consulting hospitals\u2013the rate of recognized receiving hepatitis screening and that of the unrecognized. Kanzo. 2016;57(12):634\u201348.","journal-title":"Kanzo"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-017-2438-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T06:46:02Z","timestamp":1494225962000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-017-2438-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2438"],"URL":"https:\/\/doi.org\/10.1186\/s12879-017-2438-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,8]]},"article-number":"330"}}